PREventClinic ATL

03/30/2024

The best in the business! Please help us say ‘Happy Doctors Day’ to our dedicated top doctors!!!

03/27/2024

☕️ Ozempic: The Unspoken Toll

☕️ There is an element to the GLP-1 agonist story that is getting very little attention. What is happening with apparently normal weight individuals who seek these wonder drugs?

Join us as we grind up the beans on this enlightening episode of The Health Mastery Café where we explore the complex world of GLP-1 agonists like Ozempic, not just as a weight-loss solution but through the lens of body image and mental health. In this special episode, we're honored to have Dr. Yalda Safai, a board-certified psychiatrist and seasoned TV contributor, who will shed light on the intriguing effects of these medications on individuals with normal BMIs. Despite their ineligibility based on the criteria, the allure of weight loss drives a significant interest across various demographics.

Dr. Yalda Safai discusses the psychological implications and societal pressures that might drive individuals towards these medications.

Dr. Dave addresses clinical considerations, spotlighting groups for whom GLP-1 agonists might pose risks. Furthermore, he passionately advocates against the stigmatization of low BMI individuals who express interest in these drugs and addresses the controversy surrounding the current supply shortages.

This episode promises a deep dive into the ramifications of weight loss drugs beyond the scale, fostering a conversation that juxtaposes medical insight with societal impacts. Whether you're a healthcare professional, someone considering these treatments, or just intrigued by the topic, this discussion will offer valuable perspectives on an increasingly relevant subject. Join us, as we unravel the narratives behind the headlines and explore the intersection of health, society, and self-perception.

☕️ ☕️ GLP-1s through the lens of body image and mental healthVideo Timestamps:00:00 intro03:12 New perspective for people who take GLP-1 receptor agonists, ...